Top

Annals of Nuclear Medicine

Published in:

01-12-2016 | Original Article

Assessment of ¹⁰B concentration in boron neutron capture therapy: potential of image-guided therapy using ¹⁸FBPA PET

Authors: Eku Shimosegawa, Kayako Isohashi, Sadahiro Naka, Genki Horitsugi, Jun Hatazawa

Published in: Annals of Nuclear Medicine | Issue 10/2016

Abstract

Objectives

In boron neutron capture therapy (BNCT) for cancer, the accurate estimation of ¹⁰B tissue concentrations, especially in neighboring normal organs, is important to avoid adverse effects. The ¹⁰B concentration in normal organs after loading with ¹⁰B, however, has not been established in humans. In this study, we performed 4-borono-2-[¹⁸F]-fluoro-phenylalanine (¹⁸FBPA) PET in healthy volunteers and estimated the chronological changes in the ¹⁰B concentrations of normal organs.

Methods

In 6 healthy volunteers, whole-body ¹⁸FBPA PET scans were repeated 7 times during 1 h, and the mean ¹⁸FBPA distributions of 13 organs were measured. Based on the ¹⁸FBPA PET data, we then estimated the changes in the ¹⁰B concentrations of the organs when the injection of a therapeutic dose of ¹⁰BPA–fructose complex (¹⁰BPA–fr; 30 g, 500 mg/kg body weight) was assumed.

Results

The maximum mean ¹⁸FBPA concentrations were reached at 2–6 min after injection in all the organs except the brain and urinary bladder. The mean ¹⁸FBPA concentration in normal brain plateaued at 24 min after injection. When the injection of a therapeutic dose of ¹⁰BPA–fr was assumed, the estimated mean ¹⁰B concentration in the kidney increased to 126.1 ± 24.2 ppm at 3 min after injection and then rapidly decreased to 30.9 ± 7.4 ppm at 53 min. The estimated mean ¹⁰B concentration in the bladder gradually increased and reached 383.6 ± 214.7 ppm at 51 min. The mean ¹⁰B concentration in the brain was estimated to be 7.6 ± 1.5 ppm at 57 min.

Conclusions

¹⁸FBPA PET has a potential to estimate ¹⁰B concentration of normal organs before neutron irradiation of BNCT when several assumptions are validated in the future studies.

Kawabata S, Miyatake S, Nonoguchi N, Hiramatsu R, Iida K, Miyata S, et al. Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. Appl Radiat Isot. 2009;67:S15–8.CrossRefPubMed

Miyatake S, Kawabata S, Hiramatsu R, Furuse M, Kuroiwa T, Suzuki M. Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases. Radiat Oncol. 2014;. doi:10.1186/1748-717X-9-6.

Suzuki M, Kato I, Aihara T, Hiratsuka J, Yoshimura K, Niimi M, et al. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. J Radiat Res. 2014;55:146–53.CrossRefPubMed

Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, et al. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking ¹⁰B-compound. Lancet. 1989;2:388–9.CrossRefPubMed

Kageji T, Mizobuchi Y, Nagahiro S, Nakagawa Y, Kumada H. Clinical results of boron neutron capture therapy (BNCT) for glioblastoma. Appl Radiat Isot. 2011;. doi:10.1016/j.apradiso.2011.05.029.

Wittig A, Malago M, Collette L, Huiskamp R, Bührmann S, Nievaart V, et al. Uptake of two ¹⁰B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC trial 11001). Int J Cancer. 2008;122:1164–71.CrossRefPubMed

Wittig A, Collette L, Appelman K, Bührmann S, Jäckel MC, Jöckel KH, et al. EORTC trial 11001: distribution of two ¹⁰B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial. J Cell Mol Med. 2009;13:1653–65.CrossRefPubMed

Detta A, Cruickshank GS. L-Amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res. 2009;69:2126–32.CrossRefPubMed

Watabe T, Ikeda H, Nagamori S, Wiriyasermkul P, Tanaka Y, Naka S, et al. ¹⁸FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with ¹⁸F-FDG and ¹¹C-methionine PET. Eur J Nucl Med Mol Imaging 2016 (In press).

10.

Nariai T, Ishiwata K, Kimura Y, Inaji M, Momose T, Yamamoto T, et al. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma. Appl Radiat Isot. 2009;67:S348–50.CrossRefPubMed

11.

Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot 2009;67:S37–42.

12.

Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, et al. FBPA PET in boron neutron capture therapy for cancer: prediction of ¹⁰B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res. 2014;. doi:10.1186/s13550-014-0070-2.PubMedPubMedCentral

13.

Sakata M, Oda K, Toyohara J, Ishii K, Nariai T, Ishiwata K. Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Ann Nucl Med. 2013;27:285–96.CrossRefPubMed

14.

Morris GM, Coderre JA, Hopewell JW, Micca PL, Rezvani M. Response of rat skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodium. Radiother Oncol. 1994;32:144–53.CrossRefPubMed

15.

Morris GM, Coderre JA, Micca PL, Fisher CD, Capala J, Hopewell JW. Central nervous system tolerance to boron neutron capture therapy with p-boronophenylalanine. Br J Cancer. 1997;76:1623–9.CrossRefPubMedPubMedCentral

16.

Futamura G, Kawabata S, Siba H, Kuroiwa T, Suzuki M, Kondo N, et al. A case of radiation-induced osteosarcoma treated effectively by boron neutron capture therapy. Radiat Oncol. 2014;. doi:10.1186/s13014-014-0237-z.PubMedPubMedCentral

17.

Ono K. An analysis of the structure of the compound biological effectiveness factor. J Radiat Res. 2016. (Epub ahead of print).

18.

Bergenheim AT, Capala J, Roslin M, Henriksson R. Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. J Neurooncol. 2005;71:287–93.CrossRefPubMed

19.

Elowitz EH, Bergland RM, Coderre JA, Joel DD, Chadha M, Chanana AD. Biodistribution of p-boronophenylalanine in patients with glioblastoma multiforme for use in boron neutron capture therapy. Neurosurgery. 1998;42:463–8.CrossRefPubMed

20.

Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Clin Cancer Res. 1998;4:1833–41.PubMed

21.

Pisarev MA, Dagrosa MA, Juvenal GJ. Boron neutron capture therapy in cancer: past, present and future. Arq Bras Endocrinol Metabol. 2007;51:852–6.CrossRefPubMed

22.

Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, et al. Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot. 2004;61:1069–73.CrossRefPubMed

23.

Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochem Biophys Acta. 2001;1514:291–302.CrossRefPubMed

24.

Ishiwata K, Shiono M, Kubota K, Yoshino K, Hatazawa J, Ido T, et al. A unique in vivo assessment of 4-[¹⁰B]borono-l-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[¹⁸F]fluoro-l-phenylalanine. Melanoma Res. 2009;2:171–9.CrossRef

25.

Yoshimoto M, Kurihara H, Honda N, Kawai K, Ohe K, Fujii H, et al. Predominant contribution of L-type amino acid transporter to 4-borono-2-¹⁸F-fluoro-phenylalanine uptake in human glioblastoma cells. Nucl Med Biol. 2013;40:625–9.CrossRefPubMed

26.

Kreimann EL, Itoiz ME, Dagrosa A, Garavaglia R, Farías S, Batistoni D, et al. The hamster cheek pouch as a model of oral cancer for boron neutron capture therapy studies: selective delivery of boron by boronophenylalanine. Cancer Res. 2001;61:8775–81.PubMed

Title: Assessment of 10B concentration in boron neutron capture therapy: potential of image-guided therapy using 18FBPA PET
Authors: Eku Shimosegawa
Kayako Isohashi
Sadahiro Naka
Genki Horitsugi
Jun Hatazawa
Publication date: 01-12-2016
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 10/2016
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-016-1121-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Assessment of ¹⁰B concentration in boron neutron capture therapy: potential of image-guided therapy using ¹⁸FBPA PET

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2016

Validation of a simplified scatter correction method for 3D brain PET with 15O

Respiratory-gated time-of-flight PET/CT during whole-body scan for lung lesions: feasibility in a routine clinical setting and quantitative analysis

Development of a myocardial phantom and analysis system toward the standardization of myocardial SPECT image across institutions

Correlation of HIF-1α/HIF-2α expression with FDG uptake in lung adenocarcinoma

Usefulness of the novel risk estimation software, Heart Risk View, for the prediction of cardiac events in patients with normal myocardial perfusion SPECT

Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro